The additional investments in the US will not lead to a reduction in jobs in Switzerland. This is according to pharmaceutical giant Roche, which expects the number of employees to remain stable in the current year. The position of Novartis is similar. "With our recent $50 billion (CHF 40.4 billion at today's exchange rate) investment in the US, we reaffirm our commitment to the healthcare system and patients in this region," the Basel-based company told the Keystone-SDA news agency. +Get the most important news from Switzerland in your inbox Reacting to an article in today's NZZ am Sonntag about the capacity expansion in the US, Roche added that it does not foresee any impact of the investments on employees in Switzerland and other countries for now. "We have invested billions of francs in our operations in Switzerland and Europe and will continue to do so." The Zurich Sunday paper also mentions the other major Swiss pharmaceutical group, Novartis, claiming that it intends to ...
